Clinical Scorecard: Immunometabolic Pathways and Potential Therapeutic Targets in Metabolic Dysfunction-Associated Steatohepatitis

At a Glance

Key Highlights

• MASH is a progressive subtype of MASLD characterized by hepatic steatosis and inflammation.
• Approximately 20% of MASH patients may progress to cirrhosis.
• Fibrosis stage is the strongest prognostic determinant of liver-related outcomes.
• Current pharmacotherapy options for MASH are limited.
• Immunometabolic crosstalk is crucial for understanding disease progression.
• Genetic predisposition and environmental factors critically modulate disease susceptibility.

Guideline-Based Recommendations

Diagnosis

• Histological assessment for steatosis, lobular inflammation, hepatocellular ballooning, and fibrosis.

Management

• Focus on lifestyle modifications and emerging therapeutic targets like PPARs, FXR, and GLP-1.
• Consider current pharmacotherapy options, even if limited.

Monitoring & Follow-up

• Regular assessment of fibrosis stage and metabolic comorbidities.
• Monitor for hepatocellular carcinoma risk.

Risks

• Increased risk of hepatic decompensation, hepatocellular carcinoma, and liver-related mortality.

Patient & Prescribing Data

Individuals with MASH and associated metabolic disorders.

Precision stratification and multi-target interventions are essential for effective management.

Clinical Best Practices

• Implement lifestyle changes to address obesity and metabolic syndrome.
• Monitor liver function and fibrosis progression regularly.
• Consider multi-target therapeutic strategies for individualized treatment.
• Regularly assess for hepatocellular carcinoma risk.

Related Resources & Content

• Clinical Overview of MASH
• Pathogenesis of MASH